Tradestie Institutional Equity Comparison Engine · Market Close Jul 31, 2026

PSTV vs KVAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PSTV Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–5 Matrix Metrics)

PSTV Overall Winner 6-Pillar Tally: PSTV 2 – 2 KVAC (2 Tie) Matrix Metrics: PSTV 5 – 5 KVAC

As of Jul 31, 2026, PLUS THERAPEUTICS, Inc. (PSTV) is the stronger overall head-to-head candidate over Keen Vision Acquisition Corporation (KVAC) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow). PSTV carries a Unified Composite Score of 59.8/100 (HOLD) at $3.87 (1.0x Forward P/E, -692.5% operating margin), whereas KVAC carries 58.0/100 (HOLD) at $11.51 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: PSTV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.3); meanwhile KVAC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PSTV vs KVAC
PSTV NASDAQ Head-to-Head Winner
PLUS THERAPEUTICS, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$3.87
+6.03% 1D
Market Cap $25.1M
TTM Revenue $5.2M
Forward P/E 1.0x
Beta / 30D Vol 2.04β · 50% Vol
Unified Composite Score
59.8 / 100 HOLD
Tech 45.0 Fund 53.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.0%), weak momentum, RSI 43
RSI-14: 43.3 · SMA20: $3.89 · SMA50: $4.66
KVAC US Equity
Keen Vision Acquisition Corporation
Blank Checks
$11.51
-13.13% 1D
Market Cap $73.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.17β · 76% Vol
Unified Composite Score
58.0 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A

6-Pillar Scorecard Institutional Category Breakdown (PSTV 2 – 2 KVAC)

Columns: Metric · PSTV · KVAC
1. Valuation Multiples PSTV
Forward P/E 1.0x N/M
Trailing P/E 0.2x 88.3x
PEG Ratio 2.45x N/M
EV / Revenue 4.4x N/M
2. Growth & Scale KVAC
Revenue Growth (YoY) -2.9% +0.0%
Earnings Growth (YoY) +0.0% -76.9%
TTM Revenue (USD) $5.2M N/A
Market Cap $25.1M $73.0M
3. Profitability & Quality KVAC
Gross Margin -83.1% N/A
Operating Margin -692.5% 0.0%
Net Profit Margin -230.2% 0.0%
Return on Equity (ROE) -522.5% 0.0%
4. Balance Sheet & Cash Flow PSTV
Cash Generation (TTM) -$22M -$429,086
Cash Flow Margin N/A N/A
Net Cash / Leverage $2.3M Net Cash $1.6M Net Debt (0.48x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Shell Companies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PSTV (5) vs KVAC (5)
Institutional Metric PSTV KVAC Criterion Row Edge
Market Capitalization
Scale
$25.1M $73.0M Larger Scale KVAC
Trailing P/E Ratio
Valuation
0.2x 88.3x Lower Multiple PSTV
Forward P/E Ratio
Valuation
1.0x N/M Lower Multiple PSTV
Revenue Growth (YoY)
Growth
-2.9% +0.0% Higher Growth KVAC
Operating Margin (TTM)
Profitability
-692.5% 0.0% Higher Margin KVAC
Net Profit Margin
Profitability
-230.2% 0.0% Higher Margin KVAC
Return on Equity (ROE)
Capital Efficiency
-522.5% 0.0% Higher ROE KVAC
52-Week Range Position
Momentum
48% ($0–$8) 0% ($12–$19) Stronger Trend PSTV
Beta / 30D Volatility
Risk Regime
2.04β · 50% Vol -0.17β · 76% Vol Lower Realized Risk PSTV
Unified Institutional Score
Composite Signal
59.8 / 100 (HOLD) 58.0 / 100 (HOLD) Higher Composite PSTV
Trailing 12M Revenue (USD)
Operating Scale
$5.2M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-83.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.45x PEG · 4.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$22M ($2.3M Net Cash) -$429,086 ($1.6M Net Debt (0.48x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KVAC +34.94 pp
PSTV: -41.36% · KVAC: -6.42%
3M Horizon PSTV +657.46 pp
PSTV: +655.42% · KVAC: -2.04%
6M Horizon PSTV +591.88 pp
PSTV: +590.09% · KVAC: -1.79%
1Y Horizon PSTV +591.88 pp
PSTV: +590.09% · KVAC: -1.79%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PSTV vs KVAC. Trailing 12-month operating profitability (PSTV -692.5% vs KVAC 0.0%) and valuation multiples (PSTV 1.0x vs KVAC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PSTV ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.2M
Gross Margin-83.1%
Op. Margin-692.5%
ROE / Fwd P/E-522.5% · 1.0x
KVAC ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E0.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PSTV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PSTV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KVAC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KVAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PSTV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $25.1M market capitalization and -692.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KVAC Moat Profile Cyclical / Execution-Driven Positioning
Shell Companies Operator
Competes within the Shell Companies value chain with $73.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PSTV vs KVAC Key Questions & Quantitative Answers

As of Jul 31, 2026, PLUS THERAPEUTICS, Inc. (PSTV) is the stronger overall head-to-head candidate over Keen Vision Acquisition Corporation (KVAC) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow). PSTV carries a Unified Composite Score of 59.8/100 (HOLD) at $3.87 (1.0x Forward P/E, -692.5% operating margin), whereas KVAC carries 58.0/100 (HOLD) at $11.51 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: PSTV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.3); meanwhile KVAC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KVAC leads the Growth & Scale pillar: PSTV posts -2.9% YoY revenue growth and +0.0% YoY earnings growth on $5.2M TTM revenue (-83.1% gross margin, -692.5% operating margin), compared with KVAC at +0.0% YoY revenue growth and -76.9% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PSTV generates $5.2M in USD-normalized revenue versus N/A for KVAC. In operating R&D and SG&A reinvestment, PSTV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KVAC.

PSTV screens cheaper on headline valuation multiples. PSTV trades at 1.0x Forward P/E, 0.2x Trailing P/E, 2.45x PEG, and 4.4x EV/Revenue (unreported FCF margin), whereas KVAC trades at N/M Forward P/E, 88.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PSTV (-522.5% ROE) versus KVAC (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PSTV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.04β · 50% Vol realized risk). By comparison, KVAC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.17β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Jul 31, 2026. For educational research only; not investment advice.